Tyrosine kinase inhibitorFDA-approvedSecond-line
Iressa
Generic name: gefitinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, patients with EGFR-mutated non-small cell lung cancer who received Iressa had a response rate of approximately 20%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Nanoparticle Formulation Enhances Cancer Drug's Effectiveness | Lung Cancer | lab-study | The nanosuspension showed a 33.8% higher inhibition rate than the physical mixture after 72 h. | Source → |
| Combining Traditional Chinese Medicine with Gefitinib May Help Treat Lung Cancer | Lung Cancer | lab-study | The combination therapy suppressed both the clonogenic ability and the combined processes of migration and proliferation in H1975 cells. | Source → |
| Bufalin May Help Overcome Lung Cancer Resistance to Certain Treatments | Lung Cancer | lab-study | — | Source → |
| Gefitinib Resistance in Lung Cancer: A New Pathway Discovered | Lung Cancer | lab-study | — | Source → |
| Berberine May Help Protect Liver from Gefitinib Side Effects | Lung Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.